Search filters

List of works by Klaus Podar

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

scientific article published in September 2002

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells

scientific article published on September 2005

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

scientific article

A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase ⬇️

scientific article published on September 1, 2003

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

scientific article published on 28 September 2007

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma

scientific article published on December 2003

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth

scientific article published on 14 December 2006

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications

scientific article published on 06 March 2009

Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells ⬇️

scientific article published on October 1, 2003

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

scientific article published on 12 May 2009

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib

scientific article

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

scientific article

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

scientific article published on 19 August 2004

Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies ⬇️

scientific article published on November 1, 2011

Emerging therapies for multiple myeloma

scientific article published on 01 March 2009

FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma

scientific article published on March 2006

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance

scientific article published in August 2005

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

scientific article

GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo ⬇️

scientific article published on August 31, 2012

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

scientific article published on 26 November 2003

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

scientific article

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

scientific article published on July 2005

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays

scientific article

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays

scientific article published on February 2002

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

scientific article published on December 2005

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

scientific article published on September 2007

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)

scientific article published on 22 December 2020

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

scientific article published on September 2003

JunB is a key regulator of multiple myeloma bone marrow angiogenesis

scientific article published on 18 May 2021

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo

scientific article published on 01 October 2006

MM-associated anemia: more than “crowding out” HSPCs ⬇️

scientific article published on September 27, 2012

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

scientific article published on April 2004

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.

scientific article published on April 2005

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

scientific article published on 26 September 2002

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

scientific article

Multiple myeloma

scientific article published in The Lancet

New insights, recent advances, and current challenges in the biological treatment of multiple myeloma ⬇️

scientific article published on June 17, 2013

Novel Targets and Derived Small Molecule Inhibitors in Multiple Myeloma ⬇️

scientific article published on September 1, 2012

Novel therapies targeting the myeloma cell and its bone marrow microenvironment ⬇️

scientific article published on December 1, 2001

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

scientific article published on 17 January 2006

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

scientific article published on December 2004

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

scientific article published in November 2003

Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer

scientific article published on 29 October 2018

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

scientific article published on July 2006

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

scientific article

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells

scientific article

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

scientific article published on 10 October 2006

Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma

scientific article published on April 2007

The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.

scientific article

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

scientific article published on 11 December 2003

The malignant clone and the bone-marrow environment

scientific article published on December 2007

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

scientific article published on September 19, 2011

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

scientific article

Tissue hypoxia and alterations in microvascular architecture predict glioblastoma recurrence in humans

scientific article published on 08 December 2020

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment

scientific article

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

scientific article published on 24 June 2004

Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with β1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCα Activation ⬇️

scientific article published on December 20, 2001

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

scientific article

Paulina is supported by:

About Paulina

Help